Tesamorelin dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 6 published studies are one click away.
Human trials Growth hormone axis Also called TH9507
Common use ranges
Mostly from the official drug label or its main trials, plus clinic protocols. Sources agree on 1 to 2 mg once a day. The newer label dose is 1.4 mg from a 2 mg vial.
- Half-life
- about 26 minutes in healthy people and 38 minutes in HIV patients (original label). Newer forms list 8 to 11 minutes.
- How it is taken
- subcutaneous injection
- How long people use it
- Trials ran 26 weeks with an extension to 52. Clinics often run 3 month blocks, then reassess. Some run 6 month courses with breaks.
- Mixing used for the units
- 10 mg vial + 2 mL water. 1 unit on a U-100 insulin syringe = 50 mcg.
Pick your vial size and how much water you add. The units below change to match.
10 mg vial + 2 mL water: 1 unit = 50 mcg
| Tier | Each dose | Syringe units10 mg vial + 2 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Starting [1] | 1 mg | 20 units 0.20 mL | once a day | Once a day for 2 to 4 weeks, then move up if it goes well | 10 days |
| Typical (Egrifta SV label) [2] | 1.4 mg | 28 units 0.28 mL | once a day | Once a day in the belly | 7 days |
| Typical [3] | 2 mg | 40 units 0.40 mL | once a day | Once a day, often at bedtime | 5 days |
Good to know
- Bedtime is the most common time. Clinics say 2 to 3 hours after the last meal.
- Some clinics use 5 days on, 2 days off. One source calls the evidence for that thin.
- Most prescribers cap at 2 mg a day. Higher was not studied.
- Missed a day? Skip it, do not double up.
- Label says consider stopping if IGF-1 stays high or there is no clear response.
Sources for these amounts
- Starting: FormBlends, tesamorelin dosage protocols
- Typical (Egrifta SV label): RxList, Egrifta SV
- Typical: RxList, Egrifta (original label) · FormBlends, tesamorelin dosage protocols
How long people use it: RxList, Egrifta SV · FormBlends, tesamorelin dosage protocols · Perfect B, tesamorelin week by week
Half-life: Egrifta FDA label 2012, section 12.3 · Egrifta WR FDA label 2025, section 12.3
Take the Tesamorelin chart with you
Get a one-page printable chart for Tesamorelin, with the syringe units for each vial and water mix. We can also email you when a new Tesamorelin study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 6 published studies
Amounts given to people in studies
How it was given: Under the skin (SC)
Every phase 3 trial used 2 mg daily.
Amounts given to animals in studies
Every study used for this page
Proof grade: Human trials. Tested in randomized human trials. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 160520832005 | Human, HIV with excess abdominal fat, phase 2 (n=61) | Placebo, 1 mg, or 2 mg TH9507 (tesamorelin) | SC | Once daily | 12 weeks | IGF-I +48% (1 mg), +65% (2 mg). Trunk fat 0.8, -4.6, -9.2% (placebo, 1, 2 mg). Visceral fat -5.4, -3.6, -15.7% (not significant vs placebo) |
| PMID 180573382007 | Human, HIV with abdominal fat, phase 3 (n=412) | 2 mg tesamorelin vs placebo | SC | Once daily | 26 weeks | Visceral fat -15.2% vs +5.0%; IGF-I +81.0% |
| PMID 201011892010 | Human, HIV, phase 3 with extension (n=404) | 2 mg daily vs placebo (2:1); extension: continue 2 mg or switch to placebo | SC | Once daily | 12 months (26-wk efficacy phase) | VAT -10.9% vs -0.6% at 6 mo; about -18% at 12 mo; effect lost on switch to placebo |
| PMID 205547132010 | Human, HIV, pooled analysis of two phase 3 (n=806) | 2 mg vs placebo (543 vs 263) | SC | Once daily | 26 wk, extended to 52 wk | VAT -24 vs +2 cm2 at wk 26; maintained to wk 52 |
| PMID 250383572014 | Human, HIV, single-center RCT (n=50) | 2 mg (n=28) vs placebo (n=22) | SC | Once daily | 6 months | VAT -34 vs +8 cm2; liver fat down (median -2.0% vs +0.9%) |
| PMID 172146112007 | Animal: pigs, rats, dogs (n not in abstract; body weights not stated) | Not stated in the abstract | IV or SC | Daily repeat | Up to 4 months (subchronic tox in rats, dogs) | GH and IGF-I rose markedly. Dogs showed adverse effects tied to long high GH/IGF-1 exposure |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
What amounts of Tesamorelin were used in human studies?
In the studies listed here, people were given from 1 mg daily up to 2 mg daily. The amount used most often was 2 mg daily. These are what study teams chose for their participants under supervision.
Where do these Tesamorelin numbers come from?
From 6 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Human trials.
How long does Tesamorelin stay in the body?
Its half-life is about 26 minutes in healthy people and 38 minutes in HIV patients (original label). Newer forms list 8 to 11 minutes. in people. Half-life is how long it takes for half of a dose to leave the blood. The effect can last longer than that.
Is this a recommendation for how much Tesamorelin to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.